Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.
The company is developing patents for cancer treatment that focuses on solid tumours, using its lead product PRP, and recently received a notice of allowance for its US patent formula.
Nathanielsz says: "This is quite an exciting development because in the US, biologicals, especially ones that are naturally derived, are quite often hard to patent.
"We've been able to identify claims that we believe were novel and inventive and the US Patent and Trademark Office agreed - this is probably the highest level of protection needed in the biggest market in the world."
